Chimerix, Inc. - Product Pipeline Review - 2014

Published: Mar, 2014 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Chimerix, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Chimerix, Inc. - Product Pipeline Review - 2014', provides an overview of the Chimerix, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Chimerix, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Chimerix, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Chimerix, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Chimerix, Inc.'s pipeline products

Reasons to buy

- Evaluate Chimerix, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Chimerix, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Chimerix, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Chimerix, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Chimerix, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Chimerix, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Chimerix, Inc. Snapshot 5
Chimerix, Inc. Overview 5
Key Information 5
Key Facts 5
Chimerix, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Chimerix, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Chimerix, Inc. - Pipeline Products Glance 13
Chimerix, Inc. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Chimerix, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Chimerix, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Chimerix, Inc. - Drug Profiles 17
brincidofovir 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Dual Active Cytomegalovirus (CMV)/Polyomavirus BK (BKV) Program 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Small Molecule For Influenza A 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Small Molecules For Influenza B 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Nucleoside Analogs For Hepatitis C 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule For Dengue 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule For Malaria 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecules For Anti-Fungal Program 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecules for Respiratory Syncytia Virus 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecules For Tuberculosis 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Chimerix, Inc. - Pipeline Analysis 28
Chimerix, Inc. - Pipeline Products by Target 28
Chimerix, Inc. - Pipeline Products by Route of Administration 29
Chimerix, Inc. - Pipeline Products by Molecule Type 30
Chimerix, Inc. - Pipeline Products by Mechanism of Action 31
Chimerix, Inc. - Recent Pipeline Updates 32
Chimerix, Inc. - Dormant Projects 40
Chimerix, Inc. - Locations And Subsidiaries 41
Head Office 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Chimerix, Inc., Key Information 5
Chimerix, Inc., Key Facts 5
Chimerix, Inc. - Pipeline by Indication, 2014 8
Chimerix, Inc. - Pipeline by Stage of Development, 2014 9
Chimerix, Inc. - Monotherapy Products in Pipeline, 2014 10
Chimerix, Inc. - Out-Licensed Products in Pipeline, 2014 11
Chimerix, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Chimerix, Inc. - Phase III, 2014 13
Chimerix, Inc. - Phase II, 2014 14
Chimerix, Inc. - Preclinical, 2014 15
Chimerix, Inc. - Discovery, 2014 16
Chimerix, Inc. - Pipeline by Target, 2014 28
Chimerix, Inc. - Pipeline by Route of Administration, 2014 29
Chimerix, Inc. - Pipeline by Molecule Type, 2014 30
Chimerix, Inc. - Pipeline Products by Mechanism of Action, 2014 31
Chimerix, Inc. - Recent Pipeline Updates, 2014 32
Chimerix, Inc. - Dormant Developmental Projects,2014 40